T9G.F Vidac Pharma Holding Plc
- Market cap
- EUR 11.8M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is T9G.F undervalued?
Graham numberThe Graham number of Vidac Pharma Holding Plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Vidac Pharma Holding Plc fundamental analysis
No fundamental analysis for Vidac Pharma Holding Plc yet.
Vidac Pharma Holding Plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Vidac Pharma Holding Plc
Vidac Pharma Holding Plc, an investment holding company, engages in the discovery and development of anticancer medicines. The company is developing VDA-1102 CTCL which is in phase 2 clinical trials for the treatment of cutaneous T cell lymphoma (CTCL); and VDA-1102 Ointment, an anti-neoplastic agent that is in phase 2B clinical trials for triggering apoptosis in cancer cells with minimal effects on surrounding normal cells. It is also developing VDA-1102 IV, an anti-neoplas…
Full company profileVidac Pharma Holding Plc financial statements
Vidac Pharma Holding Plc annual financial statements (GBP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2025 |
|---|---|---|---|
| Income Statement | |||
| Revenue | 0.00 | 0.00 | 0.00 |
| Operating Income | -609K | -1.21M | -1.90M |
| EBITDA | -608K | -1.21M | -1.90M |
| Net Income | -643K | -1.28M | -1.89M |
| EPS | -0.01 | -0.02 | -0.03 |
| Balance Sheet | |||
| Total Assets | 47.0K | 119K | 656K |
| Total Liabilities | 795K | 875K | 1.29M |
| Shareholders' Equity | -748K | -756K | -633K |
| Cash & Short-term Investments | 34.0K | 60.0K | 250K |
| Cash Flow | |||
| Operating Cash Flow | -468K | -682K | -1.73M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -468K | -682K | -1.73M |
| Ratios | |||
| ROA | -1,368.1% | -1,071.4% | -288.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
Vidac Pharma Holding Plc dividends
Vidac Pharma Holding Plc has not paid dividends in the last 3 fiscal years.
Who owns Vidac Pharma Holding Plc
Ownership data of Vidac Pharma Holding Plc is not available yet.
Vidac Pharma Holding Plc company profile
- Company name
- Vidac Pharma Holding Plc
- Ticker
- T9G.F
- ISIN
- GB00BM9XQ619
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 20-22, Wenlock Road, London, United Kingdom, N1 7GU
- Phone
- 972 54 4257381
- Website
- vidacpharma.com
About Vidac Pharma Holding Plc
Vidac Pharma Holding Plc, an investment holding company, engages in the discovery and development of anticancer medicines. The company is developing VDA-1102 CTCL which is in phase 2 clinical trials for the treatment of cutaneous T cell lymphoma (CTCL); and VDA-1102 Ointment, an anti-neoplastic agent that is in phase 2B clinical trials for triggering apoptosis in cancer cells with minimal effects on surrounding normal cells. It is also developing VDA-1102 IV, an anti-neoplastic agent; and VDA-1275, a potent small molecule new chemical entity that is in preclinical stage for use in the treatment of solid tumors. Vidac Pharma Holding Plc was founded in 2012 and is headquartered in London, the United Kingdom.
Vidac Pharma Holding Plc management
6- Dr. Max Herzberg Ph.D.Chairperson & CEO · born 1940
- Mr. Shuki Cohen CPAChief Financial Officer
- Ms. Sandra Gamzon M.B.A.Operations Manager
- Mr. Gilad Peleg-Lorberbaum M.B.A.Head of Business Development
- Dr. Oren M. Becker Ph.D.Senior Advisor of Drug Development & Board Member · born 1961
- Advocate Natalia KronikCompany Secretary